It was previously reported that the combination of IL-33 with PD-1 mAb prolongs the survival of leukemia-bearing mice [48] and PDAC mice [14] and stimulates anti-tumor responses in mouse models of Ret melanoma [13] and orthotopic lung cancer [49]. Here, RPL17 is linked to leukemia.